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IntrOductIOn
K. pneumoniae is the third common gram negative bacteria 
of nosocomial infections in burn patients after P. aeruginnosa 
and A. baumannii [1-3]. This microorganism can cause diverse 
type of infection like pneumonia, urinary tract infection, and 
septicemia etc [3,4]. These infections cause increasing morbidity 
and mortality among patients [3,5]. K. pneumoniae can persist 
on hospital environmental and can colonize human skin [4]. 
Therefore, it can easily transmit among patients via hands of 
health care personnel [4]. On the other hand over use of antibiotic 
and/or inappropriate antibiotic therapy are the major causes for 
the emergence of antibiotic resistant K. pneumoniae [3,5,6]. 
Resistance to antibiotics can contribute by different mechanism 
like efflux-pump, production of different enzymes, etc [4]. One of 
the main mechanism for resistance to beta-lactam antibiotics is the 
production of beta-lactamases including AmpC betalactamases 
(AmpC) and extended-spectrum beta-lactamases (ESBLs) [7,8]. 
AmpC beta-lactamases are group I cephalosporinases and 
can cause resistance to wide variety of beta-lactam antibiotics 
including third generation of cephalosporins and aztreonam [6,9]. 
Even AmpC may also mediate resistance to carbapenems in 
combination with porin loss [6]. One of the main characterizations 
of this enzyme is related to poor inhibition by beta-lactamases 
inhibitor like clavulanic acid [10]. AmpC is originally mediated 
chromosomally in Enterobactriaceae; however, plasmid-mediated 
AmpC beta-lactamases has arisen through the transfer from 
chromosome to plasmid and can lead to spread among different 
bacteria population including Klebsiella spp. which typically do 
not have chromosomal AmpC [6,10]. The increasing frequency of 
plasmid mediated AmpC isolates posing therapeutic challenges 
for health care worldwide by causing resistance to a variety type of 
beta-lactam antibiotics [6]. The aim of this study was to determine 
the AmpC-producer -K. pneumoniae isolated from different clinical 
isolates. 
MAterIAls And MethOds 
Bacterial Isolations
This cross-sectional study was conducted from August to December 
2013. Three hundred and three K. pneumoniae were collected from 
different clinical sources in different wards of hospital including, 
burn wound, pneumonia, septicemia and urinary tract infections, 
inpatients 17% (52) and 83% (251) outpatients, from three teaching 
hospital in Tehran. The plate of bacteria sent to Antimicrobial 
Resistance Research Center, Iran University of Medical Sciences 
for future examines. 
These isolates were identified with conventional biochemical and 
microbiological tests. Like, TSI, urea, SIM and citrate etc. 
Antibiotic susceptibility testing
Antibiotic susceptibility testing was done by disc diffusion agar 
method according to CLSI guide line [11]. Standard antibiotic discs 
were prepared from MAST Company (Mast Diagnostics, UK) and 
include:
Cefoxitin (30µg), ceftriaxone (30µg), cefotaxime (30µg), cefepime 
(30µg), imipenem (10µg), meropenem (10µg), amoxicillin-clavulanic 
acid (20/10µg), aztreonam (30µg), tobramycin (10µg), gentamicin 
(10µg), amikacin (30µg), trimethoprim-sulfamethoxazole (1.25/23.75 
µg), chloramphenicol (30µg) and tetracycline (30µg), ceftazidime (30 
µg), cefoxitin, ceftriaxone), piperacillin (100µg). 
Phenotypic detection of Ampc
Two phenotypic tests were used for identification of AmpC:
1. The increasing inhibition zone at least 5mm around meropenem 
(10µg) plus 600 µg/disc boronic acid and meropenem (10µg) 
plus 750 µg/disc cloxacillin simultaneously in comparison 
to meropenem (10µg) alone. The stock of boronic acid was 
prepared 30mg/ml and the stock of clocacillin was prepared 
37.5 mg/ml [12].
2. Double disc methods with cefoxitine (30µg) and cefepime 
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Introduction: Klebsiella pneumoniae is one of the main oppor­
tunistic pathogens which can cause different types of infections. 
Production of beta­lactamases like AmpC and ESBL mostly 
lead to beta­lactam resistance in these Gram­Negative bacteria. 
The aim of this study was the detection of AmpC­producing K. 
pneumoniae in clinical isolates.
Materials and Methods: Three hundred and three isolates of 
K. pneumoniae were identified. Double disc method including 
cefoxitin with cefepime and using boronic acid with cloxacillin 
were performed as two phenotypic methods for detection of 
AmpC. Amplification of AmpC gene was performed by PCR. 
results: Eight and three isolates showed positive results in 
double disc method and by using boronic acid with cloxacillin, 
respectively. Five isolates had specific band for AmpC gene after 
electrophoresis. 
conclusion: Our results were indicated the low prevalence of 
AmpC­producer­K. pnemoniae in Iran. On the other hand these 
two tested phenotypic methods showed low sensitivity for 
detection of AmpC. 
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(30µg). The isolates which susceptible to cefepime and resistant 
to cefoxitine were consider as an AmpC-producer isolate [13]. 
Genotypic detection of Ampc
PCR was used as a molecular test for detection of AmpC plasmid 
mediate (cmy) gene. The forward primer was 5-ATTCCGGGTATG 
GCCGT-3 and the reverse was 3-5-GGGTTTACCTCAACGGC [14]. 
The polymerase chain reaction was performed in following condition:
The first denaturation at 94°C for 5 min and 30 cycles of 94°C for 60 
s, annealing at 58°C for 60 sec, extension at 72°C for 60 sec and at 
last the final extension at 72°C for 5 min.
Isolates which showed specific band after PCR and electrophoresis 
have been sent for sequencing to Genfanavaran, Macrogen, Seoul, 
Korea. 
results
Three hundred and three isolates of K. pneumoniae were confirmed 
according to the results of biochemical and microbiological tests. 
The percentage of antibiotic resistance was showed in [Table/
Fig-1].
Eight isolates had less than 14mm inhibition zone around cefepime 
and more than 18 mm around cefoxitin according to CLSI table 
2013. On the other hand, only three isolates showed at least 5 mm 
in diameter of inhibition zone around meropenem plus boronic acid 
and meropenem plus cloxacillin simultaneously in comparison to 
meropenem alone. None of the isolates showed positive results 
in both of detection phenotypic tests. Three positive PCR isolates 
were positive in at least one of phenotypic methods that were used 
in this study (two out of eight double disc method positive and one 
out of three when use of boronic cid and cloxcillin combined with 
meropenem). Two isolates were negative in both of phenotypic 
methods with positive results in PCR [Table/Fig- 2].
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[table/Fig- 2]: Number of isolates showing positive AmpC by all three methods
Number of confirmed AmpC positive strains with PCR according to 
source of isolated bacteria was showed in [Table/Fig-3].
Source of specimens burns infection
ventilator association 
pneumonia
No. of confirmed AmpC 
positive strains
4 1
[table/Fig- 3]: Number of confirmed AmpC positive strains with PCR according to 
source of isolated bacteria
Totally, in five strains AmpC specific band was observed after 
PCR [Table/Fig- 4] and gel electrophoresis in agaros 1.5%. Direct 
sequencing of PCR amplified products was carried out using 
ABI 3730X capillary sequencer (Genfanavaran, Macrogen, Seoul, 
Korea).
[table/Fig-4]: PCR amplification fragments for detection of AmpC agene among 
K.pneumoniae isolates M: 1kb DNA size marker; lane 1; Psitive Control of AmpC; 
lane 2-4; Positive strains; lane 5; Negative Control of AmpC gene
dIscussIOn 
K. pneumoniae is one of the important Gram - negative bacteria 
in nosocomial infections [1-3,15]. Antibiotic resistant isolates make 
therapeutic challenge for physicians [3]. K. pnemoniae can produce 
variety of beta – lactamase enzymes [3,5]. Recent study was 
conducted in Iran reported the prevalence of OXA-48-producer K. 
pneumoniae [15]. Also, this study indicated the AmpC – producer K. 
pneumoniae but in low prevalence with the rate of 1.6%. The results 
of study was conducted in Turkey in west-north of Iran were showed 
the prevalence of 8% AmpC-producer K. pneumoniae isolated from 
blood culture [16]. This prevalence is more than our results because 
K. pneumoniae were isolated from hospitalized patients in Turkey 
but in our study most of specimens were isolated from outpatients. 
Despite of the low prevalence of AmpC producer K. pneumoniae in 
our tested isolates, it is notable that the different number of isolates 
was isolated from different clinical specimens. Other studies in 
Iran have indicated the higher resistance in K. pneumoniae which 
isolated from burn patients [3]. This can be due to the expand using 
of beta-lactam antibiotics in patients whome were hospitalized in 
burn ward in Iran [3,5, 6]. Since the AmpC is the cephalosporinase, 
this low prevalence of AmpC producer K. pneumoniae in our tested 
isolates can related to use of other broad spectrum antibiotics for 
empirical treatment except cephalosporins and pressure of the 
overuse of antibiotics for selection of this mechanism of antibiotic 
resistant is low. On the other hand, we can inhibit the increasing 
prevalence of AmpC producer K. pneumonia by prevention of broad 
spectrum cephalosporins misuse. 
In Pakistan that is in east – south border of Iran the rate of AmpC 
– producer – K. pneuminiae was 12% [7]. The results of study in 
China were showed 12% AmpC – producer – K. pneuminiae [4]. 
In a study that was conducted in India six out of 44 Klebsiella spp. 
(13.6%) were positive for AmpC [17].These isolates were collected 
Antibiotics CRO FOX CTX CAZ CEF IMI MEM AT TO GM AK SXT PRL C T
Percentage 
of resistance
20.8 50 55 50 43 23 23 54 100 37 79 91 65 97 91
(63) (151) (167) (163) (130) (69) (69) (164) (303) (112) (239) (276) (197) (294) (276)
[table/Fig-1]: (Number) Percentage of resistance to tested antibiotics. CRO: ceftriaxone, FOX: cefoxitin, CTX: cefotaxime, CAZ: ceftazidime, CEF: cefepime, IMI : imipenem, 
AT, aztreonam, MEM: meropenem, TO: tobramycin, GM: gentamicin, AK: amikacin, SXT: trimethoprim sulfamethoxazole, PRL: piperacillin-Tazobactam, , C: chloramphenicol, 
T: tetracycline
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from different clinical specimens [17]. In other study that was 
done in India five out of 120 K. pneumonia (94.1%) were positive 
for detection of AmpC [18]. This difference between two studies 
that were conducted in the same country (India) can be related to 
different centers that were selected for study and also, source of 
specimens. The influence of antibiotic treatment and their pressure 
for resistant bacteria selection can be different in different health 
care settings. In this regard, six of 22 K. pneumonia (27.2%) were 
positive for AmpC [19]. These results indicated the relation with the 
source of isolated bacteria, because these isolates were collected 
from blood specimens. Generally, broad spectrum antibiotics are 
using for treatment of septicemia and the pressure of antibiotic over 
use can lead to select more resistance bacteria. These results are 
equal to our finding from burn patients in current study. On the other 
hand, this subject should be considered that AmpC gene is plasmid 
mediated and can transfer to other bacteria and make complication 
in treatment of patients [10].
cOnclusIOn 
 According to finding of this study it seems that both phenotypic 
tests have low sensitivity. Thus the phenotypic method can be useful 
for primary screening. On the other hand, phenotypic methods are 
more economical than molecular methods such as PCR and also, 
phenotypic methods do not require expertise and professionals. But 
it is notable that PCR is more reliable test for detection of AmpC-
producing strains and can use for critical and important cases. 
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